Relay Therapeutics Inc (NASDAQ: RLAY) is -62.22% lower on its value in year-to-date trading and has touched a low of $4.11 and a high of $12.14 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RLAY stock was last observed hovering at around $4.26 in the last trading session, with the day’s loss setting it -0.1%.
Currently trading at $4.16, the stock is -9.34% and -23.23% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.34 million and changing -2.35% at the moment leaves the stock -38.65% off its SMA200. RLAY registered -60.42% loss for a year compared to 6-month loss of -39.71%. The firm has a 50-day simple moving average (SMA 50) of $5.4188 and a 200-day simple moving average (SMA200) of $6.781175.
The stock witnessed a -10.73% gain in the last 1 month and extending the period to 3 months gives it a -44.01%, and is -11.68% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.43% over the week and 6.82% over the month.
Relay Therapeutics Inc (RLAY) has around 323 employees, a market worth around $679.96M and $10.01M in sales. Profit margin for the company is -3449.58%. Distance from 52-week low is 1.22% and -65.73% from its 52-week high. The company has generated returns on investments over the last 12 months (-39.09%).
with sales reaching $6.08M over the same period.The EPS is expected to grow by 9.80% this year, but quarterly earnings will post -40.98% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Relay Therapeutics Inc (RLAY) Top Institutional Holders
274.0 institutions hold shares in Relay Therapeutics Inc (RLAY), with institutional investors hold 100.16% of the company’s shares. The shares outstanding are 166.89M, and float is at 123.36M with Short Float at 9.67%. Institutions hold 98.44% of the Float.
The top institutional shareholder in the company is SB INVESTMENT ADVISERS (UK) LTD with over 27.9 million shares valued at $181.94 million. The investor’s holdings represent 21.0093% of the RLAY Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 11.7 million shares valued at $76.32 million to account for 8.8125 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 10.54 million shares representing 7.9375% and valued at over $68.74 million, while CASDIN CAPITAL, LLC holds 6.3608 of the shares totaling 8.45 million with a market value of $55.08 million.
Relay Therapeutics Inc (RLAY) Insider Activity
The most recent transaction is an insider sale by Patel Sanjiv, the company’s President and CEO. SEC filings show that Patel Sanjiv sold 100,000 shares of the company’s common stock on Dec 16 ’24 at a price of $5.00 per share for a total of $0.5 million. Following the sale, the insider now owns 0.57 million shares.
Still, SEC filings show that on Oct 28 ’24, Rahmer Peter () disposed off 1,621 shares at an average price of $6.06 for $9823.0. The insider now directly holds 390,063 shares of Relay Therapeutics Inc (RLAY).
